Essence of this Article
Several new anticoagulants that target various factors of the coagulation cascade are in development. These include tecarfarin and betrixaban.
New anticoagulants are in development that target various factors of the coagulation cascade.
Additional oral anticoagulant studies for stroke prevention in patients with atrial fibrillation
|Tecarfarin||VKOR||40 mg od (dose adjusted to INR 2.0–3.0)||Tecarfarin-CLN-504||II||Completed||[PubMed]541|
|Betrixaban||Factor Xa||40, 60 or 80 mg od||EXPLORE-Xa||II||Completed||[PubMed]542|
|INR, international normalized ratio; od, once daily; VKOR, vitamin K epoxide reductase.|